抗Hp三联疗法联合瑞舒伐他汀治疗EHCAS合并Hp感染者的临床效果

Anti-Hp triple therapy combined with rosuvastatin for patients with EH CAS and Hp infection

目的观察抗幽门螺杆菌（Hp）三联疗法联合瑞舒伐他汀治疗原发性高血压（EH）颈动脉粥样硬化（CAS）合并Hp感染者的效果。方法选择49例EHCAS合并Hp感染者，采用抗Hp三联疗法联合瑞舒伐他汀治疗，观察血脂、高敏C-反应蛋白（hs—CRP）、同型半胱氨酸（HCY）和颈动脉内膜中层厚度（CAIMT）水平变化，临床疗效及Hp感染的转阴情况。结果EHCAS合并Hp感染者治疗2周后，血清TG、TC、LDL—C、HDL—C及HCY、hs—CRP水平均有显著变化（P〈0．01），CAIMT值显著降低（P〈0．01）。总有效率为93．9％，Hp感染者转阴率为81．6％。结论抗Hp三联疗法联合瑞舒伐他汀治疗原发性高血压颈动脉粥样硬化合并Hp感染者可显著降低其炎性反应，改善其血脂、HCY水平及颈动脉粥样硬化，临床疗效及Hp感染的转阴率显著，且安全可靠。

Objective To observe the effect of anti-Hp triple therapy combined with rosuvastatin for patients with EH CAS and Hp infection. Methods 49 patients with EH CAS and Hp infection were selected and treated with anti-Hp triple therapy and rosuvastatin. The changes of the levels of blood lipids, hs-CRP, and HCY and CAIMT, the clinical efficacy, and the negative conversion ratio of Hp infection were observed. Results After 2 weeks＇ treatment, the serum levels of TG, TC, LDL-C, HDL-C, HCY, and hs-CRP obviously changed （P〈0.01） and CAIMT notably decreased （P〈0.01）. The total efficacy was 93.9% and the negative conversion ratio was 81.6%. Conelusions Anti-Hp triple therapy combined with rosuvastatin for patients with EH CAS and Hp infection can obviously decrease inflammatory reaction and improve the levels of blood lipids and HCY and CAS, has a high negative conversion ratio of lip infection, and is curatively effective, safe, and reliable.